# Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

> **NCT02953457** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 40 (actual)

## Conditions studied

- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Ovarian Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Olaparib
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT02953457
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-29
- **Primary completion:** 2021-09-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953457, "Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02953457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*